重新评估青霉素和头孢曲松MIC预测肺炎链球菌对口服头孢泊肟的敏感性
根据CLSI指南,对口服青霉素敏感的肺炎链球菌可被认为对包括口服头孢菌素在内的多种β-内酰胺类敏感,但对口服青霉素非敏感的菌株则无法预测头孢泊肟敏感性。本研究评估了青霉素折点预测美国医院近期收集的肺炎链球菌对头孢泊肟和头孢曲松敏感性的能力。结果显示,口服青霉素敏感折点(≤0.06 mg/L)可预测头孢泊肟和头孢曲松敏感,但非敏感菌株(MIC>0.06 mg/L)对头孢泊肟的敏感性无法预测(分类一致率78.4%)。
要点
- 口服青霉素敏感(MIC≤0.06 mg/L)可预测头孢泊肟和头孢曲松敏感。
- 口服青霉素非敏感菌株不能被认为对头孢泊肟敏感。
- 头孢曲松MIC可用于替代检测头孢泊肟敏感性,但需采用更低折点。
核心结论
- 对口服青霉素非敏感的肺炎链球菌不能被认为对头孢泊肟敏感,经验性使用口服头孢菌素治疗社区获得性细菌性肺炎需谨慎。
研究设计与样本
- 本研究评估了青霉素折点预测美国医院近期收集的肺炎链球菌对头孢泊肟和头孢曲松敏感性的能力,依据CLSI指南。
主要发现
- 口服青霉素敏感折点(≤0.06 mg/L)可预测头孢泊肟和头孢曲松敏感。
- 口服青霉素非敏感菌株(MIC>0.06 mg/L)对头孢泊肟的敏感性无法预测,分类一致率(CA)为78.4%。
- 胃肠外青霉素折点也无法预测头孢泊肟敏感性,极重大误差数升高且CA为76.8%,但仍可作为预测头孢曲松敏感性的替代标志物。
- 头孢曲松可用于头孢泊肟的替代检测,采用低于当前临床折点的折点(敏感≤0.25 mg/L;中介0.5 mg/L;耐药≥1 mg/L)。
关键数值与推荐
- 口服青霉素敏感折点:MIC≤0.06 mg/L。
- 头孢曲松替代头孢泊肟的折点:敏感≤0.25 mg/L;中介0.5 mg/L;耐药≥1 mg/L。
临床怎么用
- 对口服青霉素非敏感的肺炎链球菌,不应经验性使用口服头孢菌素如头孢泊肟治疗。
- 在无法直接检测头孢泊肟敏感性时,可考虑使用头孢曲松MIC替代检测,但需采用更低折点。
局限性
- 常见自动化药敏系统对口服头孢菌素测试有限,且纸片扩散法对肺炎链球菌β-内酰胺类不可靠。
- 菌株流行病学和血清型不断演变,可能影响结果外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical and Laboratory Standards Institute (CLSI) M100Ed24 (2024) states that Streptococcus pneumoniae susceptible to oral penicillin can be considered susceptible to various β-lactams, including oral cephalosporins. However, surrogacy guidance is not available for isolates nonsusceptible to oral penicillin. Instead, such isolates require specific MIC testing and interpretations for reporting susceptibility to oral cephalosporins, for which susceptibility testing is limited in most automated systems, and consequently restricts information pertaining to oral cephalosporins at an individual institution. This study evaluated the ability of the penicillin breakpoints to predict cefpodoxime and ceftriaxone susceptibilities against a recent collection of S. pneumoniae from United States hospitals according to CLSI guidelines. The susceptible breakpoint for oral penicillin (≤0.06 mg/L) predicted susceptibility to cefpodoxime and ceftriaxone. However, when isolates were nonsusceptible to oral penicillin (MIC, >0.06 mg/L), susceptibility to cefpodoxime could not be predicted due to a low categorical agreement (CA) (78.4%). Parenteral penicillin breakpoints also could not predict cefpodoxime susceptibility due to the elevated number of very major errors and a CA of 76.8%; however, these breakpoints could still be used as a surrogate marker to predict ceftriaxone susceptibility. Finally, ceftriaxone could be used for surrogate testing of cefpodoxime by applying breakpoints (≤0.25 mg/L for susceptible; 0.5 mg/L for intermediate; ≥1 mg/L for resistant) lower than the current clinical cutoffs. These analyses showed that isolates nonsusceptible to oral penicillin cannot be considered susceptible to cefpodoxime, and caution should be used when prescribing oral cephalosporins for the empiric treatment of community-acquired bacterial pneumonia.IMPORTANCESusceptibility results to oral cephalosporins are rarely available to guide therapy due to the limited number of drugs evaluated on common automated antimicrobial susceptibility testing (AST) systems (i.e., Vitek 2, MicroScan, and Phoenix). In addition, disk diffusion methods for determining Streptococcus pneumoniae susceptibility to β-lactam agents are not reliable, and a quantitative method, such as broth microdilution or gradient strips, is required. In addition, the epidemiology and serotypes of S. pneumoniae are constantly evolving; therefore, this work provides a re-evaluation of surrogacy testing for β-lactam agents against S. pneumoniae recently recovered from United States laboratories. The data provide the possible use of ceftriaxone MIC for determining cefpodoxime susceptibility. This should be of interest to microbiology laboratories and the scientific community.
引用
- Mendes RE, Pierce JV, Wright K, et al. Re-evaluation of penicillin and ceftriaxone MIC results to predict susceptibility to the oral cephalosporin, cefpodoxime, in Streptococcus pneumoniae clinical isolates from the United States according to CLSI guidelines (2019-2021). J Clin Microbiol. 2025. PMID: 40552822. doi:10.1128/jcm.00027-25
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。